Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer

Cancer Letters

Volumn 379, Issue 1, 2016, Pages 1-11

  Ju, Huai Qiang ^a,b   Zhuang, Zhuo Nan ^b,c   Li, Hao ^a,b   Tian, Tian ^a   Lu, Yun Xin ^a   Fan, Xiao Qiang ^b   Zhou, Hai Jun ^b   Mo, Hai Yu ^a   Sheng, Hui ^a   Chiao, Paul J ^b   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Aerobic glycolysis; miR 206; NAD; Nampt; Pancreatic cancer

Indexed keywords

DAPORINAD; GEMCITABINE; K RAS PROTEIN; MICRORNA; MICRORNA 206; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN P16; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CYTOKINE; DEOXYCYTIDINE; ENZYME INHIBITOR; MIRN206 MICRORNA, HUMAN; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLIC INHIBITION; MOUSE; MOUSE MODEL; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; 3' UNTRANSLATED REGION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BINDING SITE; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; ACRYLAMIDES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BINDING SITES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GLYCOLYSIS; HUMANS; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PANCREATIC NEOPLASMS; PIPERIDINES; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979505695     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.05.024     Document Type: Article

References (35)

1. [1] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
2. [2] Hammoudi, N., Ahmed, K.B., Garcia-Prieto, C., Huang, P., Metabolic alterations in cancer cells and therapeutic implications. Chin. J. Cancer 30 (2011), 508–525.
3. [3] Kroemer, G., Pouyssegur, J., Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13 (2008), 472–482.
4. [4] Garten, A., Petzold, S., Korner, A., Imai, S., Kiess, W., Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab 20 (2009), 130–138.
5. [5] Chiarugi, A., Dolle, C., Felici, R., Ziegler, M., The NAD metabolome–a key determinant of cancer cell biology. Nat. Rev. Cancer 12 (2012), 741–752.
6. [6] Khan, J.A., Forouhar, F., Tao, X., Tong, L., Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin. Ther. Targets 11 (2007), 695–705.
7. [7] Chini, C.C., Guerrico, A.M., Nin, V., Camacho-Pereira, J., Escande, C., Barbosa, M.T., et al. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin. Cancer Res 20 (2014), 120–130.
8. [8] Arora, S., Bhardwaj, A., Singh, S., Srivastava, S.K., McClellan, S., Nirodi, C.S., et al. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappaB- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4. J. Biol. Chem 288 (2013), 21197–21207.
9. [9] Melisi, D., Xia, Q., Paradiso, G., Ling, J., Moccia, T., Carbone, C., et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J. Natl. Cancer Inst 103 (2011), 1190–1204.
10. [10] Semenza, G.L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29 (2010), 625–634.
11. [11] Chang, Z., Li, Z., Wang, X., Kang, Y., Yuan, Y., Niu, J., et al. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin. Cancer Res 19 (2013), 549–559.
12. [12] Chang, Z., Ju, H., Ling, J., Zhuang, Z., Li, Z., Wang, H., et al. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS ONE, 9, 2014 e101452.
13. [13] Ju, H.Q., Gocho, T., Aguilar, M., Wu, M., Zhuang, Z.N., Fu, J., et al. Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation. Mol. Cancer Ther 14 (2015), 788–798.
14. [14] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin 63 (2013), 11–30.
15. [15] Bardeesy, N., DePinho, R.A., Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2 (2002), 897–909.
16. [16] Hur, K., Toiyama, Y., Schetter, A.J., Okugawa, Y., Harris, C.C., Boland, C.R., et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J. Natl. Cancer Inst, 107, 2015, 10.1093/jnci/dju492.
17. [17] Keklikoglou, I., Hosaka, K., Bender, C., Bott, A., Koerner, C., Mitra, D., et al. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene 34 (2015), 4867–4878.
18. [18] Ju, H.Q., Li, H., Tian, T., Lu, Y.X., Bai, L., Chen, L.Z., et al. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. J. Pineal Res 60 (2016), 27–38.
19. [19] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin 65 (2015), 5–29.
20. [20] Yuan, S., Lu, Y., Yang, J., Chen, G., Kim, S., Feng, L., et al. Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res. Ther, 6, 2015, 198.
21. [21] Singh, D., Upadhyay, G., Srivastava, R.K., Shankar, S., Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochim. Biophys. Acta 1856 (2015), 13–27.
22. [22] Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
23. [23] Son, J., Lyssiotis, C.A., Ying, H., Wang, X., Hua, S., Ligorio, M., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496 (2013), 101–105.
24. [24] Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sananikone, E., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 (2012), 656–670.
25. [25] Lyssiotis, C.A., Cantley, L.C., Targeting metabolic scavenging in pancreatic cancer. Clin. Cancer Res 20 (2014), 6–8.
26. [26] Bauer, L., Venz, S., Junker, H., Brandt, R., Radons, J., Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1. Int. J. Oncol 35 (2009), 97–107.
27. [27] Wang, J., Tsouko, E., Jonsson, P., Bergh, J., Hartman, J., Aydogdu, E., et al. miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. Mol. Oncol 8 (2014), 1690–1702.
28. [28] Lin, F., Yao, L., Xiao, J., Liu, D., Ni, Z., MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. Onco Targets Ther 7 (2014), 1583–1591.
29. [29] Wang, X.W., Xi, X.Q., Wu, J., Wan, Y.Y., Hui, H.X., Cao, X.F., MicroRNA-206 attenuates tumor proliferation and migration involving the downregulation of NOTCH3 in colorectal cancer. Oncol. Rep 33 (2015), 1402–1410.
30. [30] Zhang, L., Xia, L., Zhao, L., Chen, Z., Shang, X., Xin, J., et al. Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis. Carcinogenesis 36 (2015), 390–399.
31. [31] Chan, S.L., Chan, S.T., Chan, E.H., He, Z.X., Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin. J. Cancer 33 (2014), 267–276.
32. [32] Chan, M., Gravel, M., Bramoulle, A., Bridon, G., Avizonis, D., Shore, G.C., et al. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Res 74 (2014), 5948–5954.
33. [33] Kato, H., Ito, E., Shi, W., Alajez, N.M., Yue, S., Lee, C., et al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin. Cancer Res 16 (2010), 898–911.
34. [34] Maftouh, M., Avan, A., Sciarrillo, R., Granchi, C., Leon, L.G., Rani, R., et al. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br. J. Cancer 110 (2014), 172–182.
35. [35] Zhang, M., Fan, H.Y., Li, S.C., Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma. Biomed. Pharmacother 73 (2015), 123–128.